Q4 FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 24, 2026
Neurogene Inc. (NGNE) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$24.1 million. As of Jun 30, 2026 it held $225.4 million in cash and investments and $8.3 million in total debt.
Revenue
$0
Net income
$-34.49M
-56.6% vs year-ago quarter
Operating cash flow
$-23.76M
-22.1% vs year-ago quarter
Free cash flow
$-24.11M
-23.0% vs year-ago quarter
EPS
$-1.53
-45.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
20.01M
+40.2% vs year-ago quarter
Net cash
$217.05M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NGNE (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1404644
- Former names
- Neoleukin Therapeutics, Inc. (until Dec 6, 2023); AQUINOX PHARMACEUTICALS, INC (until Aug 12, 2019); AQUINOX PHARMACEUTICALS (USA) INC (until Dec 24, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $0 | $0 |
| Operating income | -$36.7M | -$33.3M | -$27.5M | -$23.8M | -$26.1M |
| Net income | -$34.5M | -$30.9M | -$24.7M | -$21.0M | -$22.0M |
| Diluted EPS | -$1.53 | -$1.39 | -$1.12 | -$0.99 | -$1.05 |
| Operating cash flow | -$23.8M | -$26.1M | -$17.4M | -$19.5M | -$19.5M |
| Free cash flow | -$24.1M | -$26.4M | -$17.6M | -$19.6M | -$19.6M |
| Total assets | $244.4M | $263.1M | $288.6M | $287.8M | $297.3M |
| Total liabilities | $27.2M | $25.4M | $23.7M | $22.3M | $24.1M |
| Stockholders' equity | $217.1M | $237.8M | $264.9M | $265.5M | $273.3M |
| Cash and investments | $225.4M | $243.2M | $269.0M | $265.4M | $274.5M |
| Total debt | $8.3M | $9.1M | $9.9M | $10.2M | $11.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jul 2, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 29, 2026 | Jun 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 8, 2026 | Jun 8, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 4, 2026 | Jun 3, 2026 |
All 750 Neurogene Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.